**Abernethy 1985** Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985 Sep;38(3):342-9. doi: 10.1038/clpt.1985.183. PMID: 4028631.

**Abernethy 1993** Abernethy DR, Wainer IW, Longstreth JA, Andrawis NS (1993) Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. The Journal of pharmacology and experimental therapeutics 266(2):904–11

**Barbarash 1988** Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988 Nov;94(5):954-9.

**Blume 1983** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Blume 1994** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Blume 1987** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Blume 1989** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Blume 1990** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Blume 1994** Blume H, Mutschler E (1989) Bioäquivalenz: Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel: Anleitung, Methoden, Materialien. Govi-Verlag

**Boehringer 2018** Boehringer Ingelheim Pharma GmbH & Co KG (2018) The effect of potent inhibitors of drug transporters (verapamil, rifampin, cimetidine, probenecid) on pharmacokinetics of a transporter probe drug cocktail consisting of digoxin, furosemide, metformin and rosuvastatin. EudraCT 2017-001549-29. https://clinicaltrials.gov/ct2/show/record/NCT03307252, accessed: 2020-02-25

**Choi 2008** Choi DH, Shin WG, Choi JS (2008) Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. European journal of clinical pharmacology 64(5):445–9

**Döppenschmitt 1999** Döppenschmitt S, Langguth P, Regårdh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. PMID: 9862789.

**Eichelbaum 1984** Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984 Apr;17(4):453-8. doi: 10.1111/j.1365-2125.1984.tb02371.x. PMID: 6721991; PMCID: PMC1463390.

**Freedman 1981** Freedman SB, Richmond DR, Ashley JJ, Kelly DT (1981) Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clinical pharmacology and therapeutics 30(5):644–52

**Härtter 2012** Härtter S, Sennewald R, Nehmiz G, Reilly P (2012) Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. British journal of clinical pharmacology 75(4):1053–62

**Hasegawa 1984** Hasegawa J, Fujita T, Hayashi Y, Iwamoto K, Watanabe J. pKa determination of verapamil by liquid-liquid partition. J Pharm Sci. 1984 Apr;73(4):442-5. doi: 10.1002/jps.2600730405. PMID: 6726625.

**Hansch  1995** Hansch C, Leo A, Hoekman D (1995) Exploring QSAR: Hydrophobic, electronic, and steric constants. American Chemical Society, Washington, DC

**Heikkinen 2012** Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012 Sep 29;47(2):375-86. doi: 10.1016/j.ejps.2012.06.013. Epub 2012 Jul 1.

**Hla 1987** Hla KK, Henry JA, Latham AN. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol. 1987 Nov;24(5):661-4.

**Joergenson 1988** Jørgensen NP, Walstad RA. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Pharmacol Toxicol. 1988 Aug;63(2):105-7.

**John 1992** John DN, Fort S, Lewis MJ, Luscombe DK (1992) Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers. British journal of clinical pharmacology 33(6):623–7

**Johnson 2001** Johnson BF, Cheng SL, Venitz J. Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. J Clin Pharmacol. 2001 Nov;41(11):1248-56.

**Johnston 1981** Johnston A, Burgess CD, Hamer J. Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol. 1981 Sep;12(3):397-400.

**Karim 1995** Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin Pharmacol Ther. 1995 Aug;58(2):174-84.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Maeda 2011** Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, Sugiyama Y (2011) Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clinical pharmacology and therapeutics 90(2):263–70

**McAllister 1982** McAllister RG Jr, Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418-26.

**Mikus 1990** Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK (1990) Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. The Journal of pharmacology and experimental therapeutics 253(3):1042–8

**Mooy 1985** Mooy J, Schols M, v Baak M, v Hooff M, Muytjens A, Rahn KH (1985) Pharmacokinetics of verapamil in patients with renal failure. European journal of clinical pharmacology 28(4):405–10

**Nishimura 2003** Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S. & Satoh, T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. J. Pharm. Soc. Japan 123, 369–75 (2003).

**Pauli-Magnus 2000** Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. PMID: 10773005.

**Perdaems 2010** Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet. 2010 Apr;49(4):239-58.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Ratiopharm 1988** ratiopharm GmbH (2016) Fachinformation Verapamil-ratiopharm® N 40 mg / 80 mg Filmtabletten

**Ratiopharm 1989** ratiopharm GmbH (2016) Fachinformation Verapamil-ratiopharm® N 40 mg / 80 mg Filmtabletten

**Rowland-Yeo 2011** Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci. 2011 Jun 14;43(3):160-73.

**Sanaee 2011** Sanaee F, Clements JD, Waugh AW, Fedorak RN, Lewanczuk R, Jamali F. Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol. 2011 Nov;72(5):787-97. doi: 10.1111/j.1365-2125.2011.04019.x. PMID: 21592185; PMCID: PMC3243013.

**Sandström 1999** Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol. 1999 Aug;48(2):180-9.

**Sawicki 2002** Sawicki W, Janicki S (2002) Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. International journal of pharmaceutics 238(1-2):181–9

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 

**Shand 1981** Shand DG, Hammill SC, Aanonsen L, Pritchett EL. Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther. 1981 Nov;30(5):701-6. 

**Shirasaka 2008** Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008 Jan;97(1):553-65. doi: 10.1002/jps.21114. PMID: 17828734.

**Sigma-Aldrich 2013** Sigma-Aldrich Inc (2013) A Case Study in SPE Method Development - Understanding the Dual Interaction Properties of Discovery DSC-SCX SPE Using Verapamil (and Metabolite) from Serum as a Test Example.

**Smith 1984** Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL (1984) Influence of cimetidine on verapamil kinetics and dynamics. Clinical pharmacology and therapeutics 36(4):551–4

**Streit 2005** Streit M, Göggelmann C, Dehnert C, Burhenne J, Riedel KD, Menold E, Mikus G, Bärtsch P, Haefeli WE. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol. 2005 Mar;61(1):39-46.

**Tracy 1999** Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999 May;47(5):545-52.

**van Haarst 2009** van Haarst AD, Dijkmans AC, Weimann HJ, Kemme MJB, Bosch JJ, Schoemaker RC, Cohen AF, Burggraaf J (2009) Clinically important interaction between tedisamil and verapamil. Journal of clinical pharmacology 49(5):560–7

**Vogelpoel 2004** Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004 Aug;93(8):1945-56.

**Vogelgesang 1984** Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M (1984) Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. British journal of clinical pharmacology 18(5):733–40

**Wang 2013** Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302. doi: 10.1016/j.ejps.2013.07.012. Epub 2013 Jul 31. PMID: 23916407.

**Wing 1985** Wing LM, Miners JO, Lillywhite KJ (1985) Verapamil disposition–effects of sulphinpyrazone and cimetidine. British journal of clinical pharmacology 19(3):385–91

**Wishart 2006** Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72. doi: 10.1093/nar/gkj067. PMID: 16381955; PMCID: PMC1347430.